Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.
作者信息
Ryan Julie L, Krishnan Sunil, Movsas Benjamin, Coleman C Norman, Vikram Bhadrasain, Yoo Stephen S
机构信息
Departments of Dermatology & Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA.
出版信息
Radiat Res. 2011 Nov;176(5):688-91. doi: 10.1667/rr2704.1. Epub 2011 Sep 1.
Abstract
摘要
相似文献
1
Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.降低癌症治疗的不良反应：美国国立癌症研究所关于辐射损伤缓解剂/防护剂临床前开发的研讨会
Radiat Res. 2011 Nov;176(5):688-91. doi: 10.1667/rr2704.1. Epub 2011 Sep 1.
2
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.降低癌症治疗的不良反应：美国国家癌症研究所关于辐射损伤缓解剂临床开发的指南。
Clin Cancer Res. 2011 Jan 15;17(2):222-8. doi: 10.1158/1078-0432.CCR-10-1402. Epub 2010 Nov 3.
3
Pharmacologic approaches to radiation protection.辐射防护的药理学方法。
J Clin Oncol. 2007 Sep 10;25(26):4084-9. doi: 10.1200/JCO.2007.11.5816.
4
Radioprotectors and mitigators of radiation-induced normal tissue injury.辐射诱导正常组织损伤的放射防护剂和减轻剂。
Oncologist. 2010;15(4):360-71. doi: 10.1634/theoncologist.2009-S104.
5
Radiation protectants: current status and future prospects.辐射防护剂：现状与未来展望。
Health Phys. 2006 Mar;90(3):276; author reply 276-7. doi: 10.1097/00004032-200603000-00013.
6
Radioprotective countermeasures for radiation injury (Review).辐射损伤的放射防护对策（综述）。
Mol Med Rep. 2023 Mar;27(3). doi: 10.3892/mmr.2023.12953. Epub 2023 Feb 17.
7
The role of amifostine as a radioprotector.氨磷汀作为一种辐射防护剂的作用。
Oncology (Williston Park). 2001 Oct;15(10):1349-54; discussion 1357-60.
8
Radiation countermeasure agents: an update.辐射对策剂：最新进展。
Expert Opin Ther Pat. 2010 Jan;20(1):73-101. doi: 10.1517/13543770903490429.
9
Animal models for radiation injury, protection and therapy.辐射损伤、防护与治疗的动物模型。
Radiat Res. 2005 Jul;164(1):100-9. doi: 10.1667/rr3388.
10
Point: Should the ALARA Concept and Image Gently Campaign Be Terminated?观点：“尽可能低剂量（ALARA）概念”和“轻柔成像运动”是否应该终止？
J Am Coll Radiol. 2016 Oct;13(10):1195-1198. doi: 10.1016/j.jacr.2016.04.023. Epub 2016 Jun 15.
引用本文的文献
1
Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.氨磷汀在放射性乳房重建中的预防作用：体外肿瘤安全性研究。
Ann Plast Surg. 2020 Oct;85(4):424-429. doi: 10.1097/SAP.0000000000002110.
2
Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion.新型小鼠耳静脉模型在评估血管辐射防护剂对放射性血管通透性和白细胞黏附影响中的应用。
Radiat Res. 2018 Jul;190(1):12-21. doi: 10.1667/RR14896.1. Epub 2018 Apr 19.
3
Mouse models for radiation-induced cancers.辐射诱发癌症的小鼠模型
Mutagenesis. 2016 Sep;31(5):491-509. doi: 10.1093/mutage/gew019. Epub 2016 May 21.
4
Vitamin E Analogs as Radiation Response Modifiers.维生素E类似物作为辐射反应调节剂
Evid Based Complement Alternat Med. 2015;2015:741301. doi: 10.1155/2015/741301. Epub 2015 Aug 20.
5
Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation.用于改善放射治疗的辐射防护剂和辐射缓解剂：加速临床转化的小企业创新研究（SBIR）通道。
Radiat Res. 2015 Sep;184(3):235-48. doi: 10.1667/RR14186.1. Epub 2015 Aug 18.
6
Radiation-induced myeloid leukemia in murine models.小鼠模型中的辐射诱导髓系白血病
Hum Genomics. 2014 Jul 25;8(1):13. doi: 10.1186/1479-7364-8-13.
7
2013 Dade W. Moeller lecture: medical countermeasures against radiological terrorism.2013年戴德·W·默勒讲座：针对放射性恐怖主义的医学应对措施
Health Phys. 2014 Aug;107(2):164-71. doi: 10.1097/HP.0000000000000082.
8
Mouse models for efficacy testing of agents against radiation carcinogenesis—a literature review.用于辐射致癌作用药物疗效测试的小鼠模型——文献综述。
Int J Environ Res Public Health. 2012 Dec 27;10(1):107-43. doi: 10.3390/ijerph10010107.
9
Normal tissue protection for improving radiotherapy: Where are the Gaps?改善放射治疗的正常组织保护：差距在哪里？
Transl Cancer Res. 2012 Jun;1(1):35-48.
10
Ionizing radiation: the good, the bad, and the ugly.电离辐射：有好有坏，也有丑陋的。
J Invest Dermatol. 2012 Mar;132(3 Pt 2):985-93. doi: 10.1038/jid.2011.411. Epub 2012 Jan 5.
本文引用的文献
1
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.降低癌症治疗的不良反应：美国国家癌症研究所关于辐射损伤缓解剂临床开发的指南。
Clin Cancer Res. 2011 Jan 15;17(2):222-8. doi: 10.1158/1078-0432.CCR-10-1402. Epub 2010 Nov 3.
2
NIAID/NIH radiation/nuclear medical countermeasures product research and development program.NIAID/NIH 辐射/核医学对策产品研究与开发计划。
Health Phys. 2010 Jun;98(6):903-5. doi: 10.1097/HP.0b013e3181bbc4df.
3
Radiation countermeasure agents: an update.辐射对策剂：最新进展。
Expert Opin Ther Pat. 2010 Jan;20(1):73-101. doi: 10.1517/13543770903490429.
4
Medical countermeasures against nuclear threats: radionuclide decorporation agents.针对核威胁的医学应对措施：放射性核素促排剂
Radiat Res. 2008 Oct;170(4):540-8. doi: 10.1667/rr1485.1.
5
Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.用于预测癌症患者化疗药物反应的直接体内异种移植肿瘤模型。
Clin Pharmacol Ther. 2009 Feb;85(2):217-21. doi: 10.1038/clpt.2008.200. Epub 2008 Nov 12.
6
Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. report of an NIAID Workshop, March 26-27, 2007.辐射复合伤的医学对策：辐射与烧伤、爆炸伤、创伤和/或脓毒症。美国国立过敏与传染病研究所研讨会报告，2007年3月26 - 27日
Radiat Res. 2008 Jun;169(6):712-21. doi: 10.1667/RR1295.1.
7
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003.用于评估辐射损伤预防、缓解及治疗药物的模型。美国国立癌症研究所研讨会报告，2003年12月3 - 4日
Radiat Res. 2004 Dec;162(6):711-28. doi: 10.1667/rr3276.
8
Radiation dose reduction by cysteine.半胱氨酸降低辐射剂量。
J Cell Comp Physiol. 1953 Dec;42(3):327-41. doi: 10.1002/jcp.1030420302.
9
Does amifostine have a role in chemoradiation treatment?氨磷汀在放化疗中起作用吗？
Lancet Oncol. 2003 Jun;4(6):378-81. doi: 10.1016/s1470-2045(03)01132-x.
Zotero 插件